1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market : Increasing Regulation Push for Tamper-resistant Drugs Driving New Generation of Opioids

A Product and Pipeline Analysis of the Opioid Therapeutics and Drug Delivery Market : Increasing Regulation Push for Tamper-resistant Drugs Driving New Generation of Opioids

  • March 2015
  • 75 pages
  • ID: 2757366

Summary

Table of Contents

This market insight provides data for the Global Opioid Therapeutics market. The analysis looks at opioid pharmaceutical pipeline drugs currently in the market and drugs that are in Phase III stage, which pose a potential threat to competitors. It also offers a competitive analysis of the drugs, and the forecast outcome and impact of each of these drugs. Opioid drugs in the current market have a space for tamper-resistant formulations. The opioids market is segmented into relapsing neuropathic pain, acute and post-operative pain, cancer-induced pain, and moderate to severe chronic pain.

Methodology and Scope

•This research service focuses on the global opioid therapeutics market with a focus on current Phase 3 candidates, detailed timelines, rational for pivotal program design, Phase 2 data review, and key opinion leader (KOL) commentary.
•A pipeline assessment is provided for all active candidates in development.
•The information contained in this research service was derived from published sources including the following: Disease organization websites; Frost & Sullivan publications, including annual research studies; Securities and Exchange Commission (SEC) filings and press releases; United States government public sources; and scientific journals.

Executive Summary

•The global opioids market stands at around $ x billion in 2013 and is set to grow to about $ x billion, with new drugs entering the market.
•The increasing global aging population, rising incidence of cancer, and increasing number of surgeries, especially in the developed regions, spur the usage of opioids.
•Moderate to severe chronic pain therapeutics market is the most mature one and the largest opioid market segment, holding nearly x % of the market share.
•Prevalence is highest for acute and post-operative pain affecting nearly x billion people globally, compared to other pain segments.
•With the patent expiry of oxycodone in 2014, there is a gap in the chronic pain market. The Food and Drug Administration (FDA), however, refuses to approve any generics due to safety concerns.
•Patent expiration of Oxycontin and bad press for Purdue Pharma will boost sales of the newly-approved Zohydro ER drug for chronic pain.
•Oxycodone remained the largest revenue contributor to the pain therapeutics market in 2013, with revenues worth $ x billion.
•With patent expiration of Lidoderm, sales of Butrans transdermal pain patches have almost tripled since 2011, with US sales of $ x million in 2013.
•There are 20+ orally-delivered, marketed products with the majority of prescriptions being for immediate-release generic opioids.
•The pain therapeutics pipeline is dominated by tamper-resistant formulations (TRFs), predominately because these new formulations are endorsed by the FDA, deter abuse, and enable previously genericized products to remain branded.
•Stricter regulations in the United States are one of the main reasons why many companies and manufacturers are shifting focus to European and Asian countries like China where regulations are far more lenient.
•Branded products—such as TRFs—that lack generic formulations continue to succeed in capturing significant market share.

Regulatory Overview

In January 2013, the FDA issued a draft of abuse-deterrence study requirements for inclusion in product labeling.
The increasing number of abuse and recent scrutinization of key companies like Purdue has reinforced FDA’s stand on only approving tamper-resistant formulations.
•There is potential for pain-reducing drugs without TRF technology to be removed from the market, thus creating significant market opportunity for new TRF therapies to remain branded.
•New labeling falls into x suggested tiers to describe abuse-deterrent properties including:
oFormulation with physicochemical barriers
oReduction/blockage of opioid effect when the product is manipulated
oMeaningful reduction in abuse
oDemonstrated reduced abuse in the community
•All safety categories will likely be required for all tiers, with Tier III requiring clinical abuse potential studies and Tier IV requiring post-marketing data.

Purdue Pharma
FDA’s lack of approval of generic oxycodone allows Purdue Pharma to develop a tamper-resistant formulation of Oxycodone which is currently in Phase 3 of development. The company will soon seek approval from the FDA.
•Oxycontin is Purdue’s oxycodone ER TRF, which holds an estimated % of total prescription share value or $ x billion in US sales.
•Purdue Pharma also competes in the transdermal patch market with Butrans, which generated 2013 US sales of $ x million.
•The sales of Butrans have increased significantly since the patent expiration of Lidoderm.

Endo
Endo strongly competes both in the oral and transdermal patch markets.
•Endo’s flagship product is a transdermal patch, Lidoderm, which generated $ billion in US sales. But sales have and will continue to decrease due to patent expiration of Lidoderm and generic competition.
•Opana ER’s US sales were $ million in 2012,which slipped to $ million in 2013.

Pfizer
By 2020, Pfizer is projected to be the new leader in the pain market with a diverse portfolio including orally-delivered, transdermal, and IV candidates. This heavily depends on the success of their pipeline products.
•Pfizer recently walked away and cut its losses from its long-term investment, Remoxy, which has encountered many hurdles and has been static in the filed stage since 2008.
•Embeda: Pfizer’s pain therapy with abuse-deterrant drug was withdrawn from the market in 2013 and recently approved by the FDA. This drug is in direct competition to the newly-released Zohydro ER to replace Oxycodone, whose patent expired recently.
In June 2011, Pfizer gained approval for the first immediate-release oxycodone designed to deter abuse—Oxecta. However, Oxecta’s 2013 sales were disappointing at $ x .
•Pfizer is also developing a 3-day bupivacain transdermal patch which is expected to compete with J&J’s Duragesic.

J&J
J&J competes strongly both in the transdermal patch space and orals.
•Nucynta’s immediate release and extended-release (ER) formulations had combined US sales of $ x million in 2013. J&J is currently conducting clinical trials to show the abuse-deterrence of Nucynta ER to provide a label update in 2015 or early 2016.
•Ultram ER US sales peaked in 2009 with $ x million. However, 2013 sales have declined to $ x million due to entry of generic competition.
•J&J’s transdermal patch generated 2012 US revenues of $ million, but sales have been decreasing due to generic competition.
•Clinical studies comparing Nucynta ER and Purdue’s OxyContin have confirmed the drug’s potent efficacy. Additional benefits have also been documented which will aid in the clinical argument for commercial use.
•J&J already markets this drug for acute pain and the FDA approval is significant for the company.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Labor And Delivery Global Clinical Trials Review, H2, 2017

Clinical Research in Labor And Delivery in H2, 2017

  • $ 2500
  • Industry report
  • November 2017
  • by GlobalData

Labor And Delivery Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Labor And Delivery Global Clinical Trials Review, H2, 2017" provides an overview of Labor And Delivery ...

Incisional (Ventral) Hernia Global Clinical Trials Review, H2, 2017

Clinical Research in Incisional (Ventral) Hernia in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Incisional (Ventral) Hernia Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Incisional (Ventral) Hernia Global Clinical Trials Review, H2, 2017" provides an overview ...

Ileus (Intestinal Obstruction) Global Clinical Trials Review, H2, 2017

Clinical Research in Ileus (Intestinal Obstruction) in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Ileus (Intestinal Obstruction) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Ileus (Intestinal Obstruction) Global Clinical Trials Review, H2, 2017" provides an ...


Download Unlimited Documents from Trusted Public Sources

Cardiovascular Drug and Therapy Market in the Netherlands

  • January 2018
    150 pages
  • Diuretic  

    Cardiovascular ...  

    Therapy  

  • Netherlands  

View report >

Healthcare Forecast Statistics in the US, Quarterly Update

  • January 2018
    9 pages
  • Health Insuranc...  

  • United States  

View report >

Anesthetics Market

  • January 2018
    26 pages
  • Anesthetics  

View report >

Related Market Segments :

Opioid

ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.